Etrolizumab
Etrolizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target integrin alpha-7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
433 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 14 | 11 | 1 | 2 | 30 |
| Healthy volunteers/patients | — | — | — | 12 | 2 | — | 1 | 2 | 16 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | 5 | 2 | 4 | — | 13 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 2 | 9 | 2 | — | 12 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 3 | 6 | 2 | 1 | 11 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | — | 2 | 2 | 4 | 9 |
| Bacterial infections | D001424 | — | A49 | 5 | 2 | 2 | 1 | 1 | 9 |
| Infections | D007239 | EFO_0000544 | — | 3 | 1 | 2 | 3 | 1 | 9 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | — | — | 1 | 1 | 4 |
| Respiratory tract infections | D012141 | — | J06.9 | — | 1 | 1 | 1 | 1 | 4 |
Show 43 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 27 | 34 | 5 | — | 1 | 52 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 14 | 24 | 14 | — | — | 45 |
| Myelodysplastic syndromes | D009190 | — | D46 | 13 | 17 | 2 | — | 1 | 26 |
| Hodgkin disease | D006689 | — | C81 | 5 | 6 | 1 | — | — | 10 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 2 | 2 | 6 | — | — | 10 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 2 | 1 | — | — | 7 |
| Melanoma | D008545 | — | — | 2 | 4 | 1 | — | — | 6 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 3 | 1 | — | — | 6 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 5 | — | 1 | 6 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 4 | 2 | — | — | 6 |
Show 50 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 9 | 8 | — | — | — | 13 |
| Multiple myeloma | D009101 | — | C90.0 | 5 | 6 | — | — | — | 10 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 4 | 7 | — | — | — | 8 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 3 | 6 | — | — | — | 7 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 5 | 4 | — | — | 1 | 7 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 3 | 2 | — | — | — | 5 |
| Neoplasms | D009369 | — | C80 | 4 | 2 | — | — | — | 5 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 1 | 3 | — | — | — | 4 |
| Colorectal neoplasms | D015179 | — | — | 1 | 3 | — | — | — | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 2 | — | — | 1 | 3 |
Show 94 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | 1 | — | — | — | — | 1 |
| Malaria | D008288 | EFO_0001068 | B54 | 1 | — | — | — | — | 1 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | — | — | — | — | 1 |
| Jaw fractures | D007572 | — | — | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | — | — | — | — | 2 | 2 |
| Anesthesia | D000758 | — | — | — | — | — | — | 2 | 2 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | — | — | — | 1 | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 1 | 1 |
| Snoring | D012913 | — | R06.83 | — | — | — | — | 1 | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Drug monitoring | D016903 | — | — | — | — | — | — | 1 | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 1 | 1 |
Show 18 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etrolizumab |
| INN | etrolizumab |
| Description | Etrolizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743015 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | I2A72G2V3J (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 482 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use